Lachâtre Marie, Pasquet Armelle, Ajana Faïza, Soudan Benoit, Lion Georges, Bocket Laurence, Cornavin Pauline, Senneville Eric, Boufassa Faroudy, Chéret Antoine
aDepartment of Infectious Diseases, Bichat-Claude-Bernard Hospital, AP-HPbParis Diderot University, Sorbonne Paris Cité, PariscDepartment of Infectious Diseases, Tourcoing Hospital, TourcoingdLaboratory of Biochemistry, Lille Hospital, LilleeDepartment of Nuclear Medicine, Lille Hospital, LillefLaboratory of Virology, Lille Hospital, LillegParis-Saclay University, Paris-Sud University, UVSQ, CESP U1018, INSERMhDepartment of Internal Medicine, Bicêtre Hospital, AP-HPiEA 7327 Paris Descartes University, Paris, France.
AIDS. 2017 Jan 28;31(3):451-453. doi: 10.1097/QAD.0000000000001348.
Male hypogonadism is poorly defined in people living with HIV. Using a reliable free-testosterone assay, we examined the prevalence and risk factors of male hypogonadism among people living with HIV on effective antiretroviral therapy. Male hypogonadism was found in 12.4% of patients, twice the rate reported in the general population of the same age. Two risk thresholds, namely 5 years of antiretroviral therapy and 19% total body fat, may help to identify patients at risk.
男性性腺功能减退在HIV感染者中定义不明确。我们使用可靠的游离睾酮检测方法，研究了接受有效抗逆转录病毒治疗的HIV感染者中男性性腺功能减退的患病率和危险因素。在12.4%的患者中发现了男性性腺功能减退，这一比例是同年龄普通人群报告率的两倍。两个风险阈值，即5年的抗逆转录病毒治疗和19%的体脂率，可能有助于识别有风险的患者。
